Suboptimal responses in chronic myeloid leukemia: Implications and management strategies

Cancer

Volumn 118, Issue 5, 2012, Pages 1181-1191

  Jabbour, Elias ^a   Saglio, Giuseppe ^b   Hughes, Timothy P ^c   Kantarjian, Hagop ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

chronic myeloid leukemia; dasatinib; imatinib mesylate; nilotinib; tyrosine kinase inhibitor

Indexed keywords

BOSUTINIB; DANUSERTIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BCR ABL GENE; BONE PAIN; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER RELAPSE; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EVENT FREE SURVIVAL; GENE; HUMAN; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MORTALITY; MUSCLE CRAMP; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE;

CLINICAL TRIALS AS TOPIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEDICAL ONCOLOGY; MONITORING, PHYSIOLOGIC; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PROTEIN KINASE INHIBITORS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84857359667     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26391     Document Type: Article

References (72)

1. American Cancer Society. Cancer Facts and Figures 2010. Available at: Accessed on September 1, 2010.
2. Altekruse S, Kosary C, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Available at: Accessed November 9, 2010.
3. Pasquali F, Casalone R, Francesconi D, et al. Transposition of 9q34 and 22 (q11toqter) regions has a specific role in chronic myelocytic leukemia. Hum Genet. 1979; 52: 55-67. (Pubitemid 10194799)
4. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G,. Structural organization of the bcr gene and its role in the Ph'translocation. Nature. 1985; 315: 758-761. (Pubitemid 15022931)
5. Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009; 23: 1054-1061.
6. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114: 1126.
7. Sprycel [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; 2010.
8. Tasigna [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; 2010.
9. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27: 6041-6051.
10. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994-1004. (Pubitemid 36302244)
11. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2006; 108: 1809-1820. (Pubitemid 44394987)
12. Hughes TP, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108: 28-37. (Pubitemid 43990609)
13. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. Version 2. Available at: Accessed January 24, 2011.
14. Jabbour E, Cortes JE, Kantarjian HM,. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer. 2008; 112: 2112-2118. (Pubitemid 351628619)
15. Baccarani M, Dreyling M,. Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009; 20 (suppl 4): 105-107.
16. Deininger MW,. Milestones and monitoring in patients with CML treated with imatinib. Hematology Am Soc Hematol Educ Program. 2008: 419-426.
17. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Chronic Myelogenous Leukemia. Version 2. Available at: Accessed January 24, 2011.
18. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408-2417. (Pubitemid 44903745)
19. Kantarjian HM, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006; 108: 1835-1840. (Pubitemid 44394991)
20. Piazza RG, Magistroni V, Franceschino A, et al. The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with imatinib mesylate predicts for prolonged response at 6 years. Blood Cells Mol Dis. 2006; 37: 111-115. (Pubitemid 44416272)
21. Milojkovic D, Nicholson E, Apperley JF, et al. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia. Haematologica. 2010; 95: 224-231.
22. Tam CS, Kantarjian H, Garcia-Manero G, et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood. 2008; 112: 516-518.
23. Branford S, Rudzki Z, Harper A, et al. Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia. 2003; 17: 2401-2409. (Pubitemid 38072578)
24. Wang L, Pearson K, Ferguson JE, Clark RE,. The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br J Haematol. 2003; 120: 990-999. (Pubitemid 36411558)
25. Alvarado Y, Kantarjian H, O'Brien S, et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase. Cancer. 2009; 115: 3709-3718.
26. Marin D, Milojkovic D, Olavarria E, et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood. 2008; 112: 4437-4444.
27. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346: 645-652. (Pubitemid 34815868)
28. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res. 2005; 11: 3425-3432. (Pubitemid 40627896)
29. Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood. 2008; 111: 1039-1043. (Pubitemid 351213381)
30. Kalidas M, Kantarjian H, Talpaz M,. Chronic myelogenous leukemia. JAMA. 2001; 286: 895-898. (Pubitemid 33010322)
31. Castagnetti F, Gugliotta G, Palandri F, et al. Chronic myeloid leukemia (CML) patients with "suboptimal" response to imatinib (IM) according to European LeukemiaNet criteria have a poorer outcome with respect to "optimal" responders: a GIMEMA CMLWorking Party analysis [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114: 2196.
32. Quintas-Cardama A, Kantarjian H, Jones D, et al. Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy. Blood. 2009; 113: 6315-6321.
33. Hughes TP, Hochhaus A, Branford S, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon versus STI571 (IRIS). Blood. 2010; 116: 3758-3765.
34. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362: 2251-2259.
35. Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010; 28: 2381-2388.
36. St. Charles M, Bollu VK, Hornyak E, Coombs J, Blanchette CM, DeAngelo DJ,. Predictors of treatment non-adherence in patients treated with imatinib mesylate for chronic myeloid leukemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114: 2209.
37. Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009; 113: 5401-5411.
38. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002; 8: 935-942. (Pubitemid 34520420)
39. Guilhot F, Preudhomme C, Guilhot J, et al. Significant higher rates of undetectable molecular residual disease and molecular responses with pegylated form of interferon a2a in combination with imatinib (IM) for the treatment of newly diagnosed chronic phase (CP) chronic myeloid leukaemia (CML) patients (pts): confirmatory results at 18 months of part 1 of the SPIRIT phase III randomized trial of the French CML group (FI LMC) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114: 340.
40. Hehlmann R, Jung-Munkwitz S, Lauseker M, et al. Randomized comparison of imatinib 800 mg vs. imatinib 400 mg +/- IFN in newly diagnosed BCR/ABL positive chronic phase CML: analysis of molecular remission at 12 months. The German CML-Study IV [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114: 339.
41. Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003; 101: 473-475. (Pubitemid 36077567)
42. Jabbour E, Kantarjian HM, Jones D, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood. 2009; 113: 2154-2160.
43. Kantarjian HM, Larson RA, Guilhot F, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009; 115: 551-560.
44. Koh Y, Kim I, Yoon SS, et al. Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib. Ann Hematol. 2010; 89: 725-731.
45. Zonder JA, Pemberton P, Brandt H, Mohamed AN, Schiffer CA,. The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment. Clin Cancer Res. 2003; 9: 2092-2097. (Pubitemid 36687630)
46. Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007; 109: 5143-5150. (Pubitemid 46890528)
47. Nicolini FE, Kim D-W, Ceglarek B, et al. Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): sub-analyses of the ENACT (Expanding Nilotinib Access In Clinical Trials) study [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114: 2201.
48. Powell BL, Khoury HJ, Lipton JH, Rizzieri DA, Williams D, Turner AR,. Nilotinib responses and tolerability confirmed in North American patients with chronic myeloid leukemia (CML) from ENACT (Expanding Nilotinib Access in Clinical Trials) [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114: 3295.
49. le Coutre PD, Ceglarek B, Turkina A, et al. Patterns and management of selected adverse events of adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) from the ENACT (Expanding Nilotinib Access In Clinical Trials) study [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114: 1115.
50. Yang AS, Jillella A, Miller CB, et al. Nilotinib-associated molecular responses achieved in chronic myeloid leukemia in chronic phase (CML-CP) patients with a suboptimal molecular response to imatinib [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114: 2206.
51. Miller C, Ailawadhi S, Jillella AP, et al. Patients (Pts) with Ph+ chronic myeloid leukemia in chronic phase (CML-CP) with a suboptimal molecular response to imatinib (IM) can achieve deeper responses when switched to nilotinib [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116: 2301.
52. Yeung DT, Osborn M, White DL, et al. Selective escalation of imatinib therapy and early switching to nilotinib in de novo chronic phase CML patients: interim results from the TIDEL-II trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116: 209.
53. Nilotinib Versus Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Pts With Evidence of Persistent Leukemia by RQ-PCR (ENESTcmr). Available at: Accessed April 2, 2011.
54. Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response (SENSOR). Available at: Accessed April 2, 2011.
55. Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008; 26: 3204-3212.
56. Shah NP, Cortes JE, Schiffer CA, et al. Four-year follow-up of patients with chronic-phase chronic myeloid leukemia (CP-CML) receiving 100 mg of dasatinib once daily [abstract]. J Clin Oncol. 2010; 28 (15 suppl): 6512.
57. Hughes TP, Hochhaus A, Saglio G, et al. ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116: 207.
58. Shah N, Kantarjian H, Hochhaus A, et al. Dasatinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) in the DASISION trial: 18-month follow-up [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116: 206.
59. Giles FJ, Abruzzese E, Rosti G, et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia. 2010; 24: 1299-1301.
60. Quintas-Cardama A, Kantarjian H, Jones D, et al. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure. Blood. 2007; 109: 497-499. (Pubitemid 46105944)
61. Cortes J, Talpaz M, Deininger M, et al. A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114: 643.
62. Cortes-Franco J, Dombret H, Schafhausen P, et al. Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitor, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia [abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114: 864.
63. Cortes J, Kantarjian HM, Kim D-W, et al. Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 112: 1098.
64. Khoury HJ, Kim D-W, Zaritskey A, et al. Bosutinib as third-line treatment for chronic phase chronic myeloid leukemia following failure of second-line therapy with dasatinib or nilotinib [abstract]. Blood (ASH Annual Meeting Abstracts). 2010; 116: 892.
65. Nowell PC, Hungerford DA,. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960; 25: 85-109.
66. Kantarjian HM, Cortes J, Guilhot F, Hochhaus A, Baccarani M, Lokey L,. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns. Cancer. 2007; 109: 1365-1375. (Pubitemid 46466564)
67. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008; 111: 1834-1839. (Pubitemid 351451490)
68. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007; 110: 3540-3546. (Pubitemid 350159618)
69. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 2007; 109: 2303-2309. (Pubitemid 46425867)
70. Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood. 2007; 109: 3207-3213. (Pubitemid 46572505)
71. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007; 110: 2309-2315. (Pubitemid 47523149)
72. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007; 109: 4143-4150. (Pubitemid 46743375)